Economic evaluation in collaborative hospital drug evaluation reports Ana Ortega, María Dolores Fraga, Roberto Marín-Gil, Eduardo López-Briz, Francesc Puigventós, George Dranitsaris

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain Laura Delgado-Ortega, Jordi Ginés Rubió, María del Carmen Garcías de España, David Carcedo, Luis Cordero Puentes, Carlota Moya de Alarcón

Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain Estela Moreno-Martínez, Javier de la Serna-Torraba, Vicente Escudero-Vilaplana, José Ángel Hernández-Rivas, Marina Sánchez-Cuervo, Raquel Sánchez-Hernández